Rucaparib shows promise in relapsed high-grade ovarian cancer

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Rucaparib (Rubraca) shows promising activity and a manageable safety profile in patients with relapsed BRCA1/2-mutated high-grade ovarian cancer.

Why this matters

  • Data supported FDA approval of the poly ADP-ribose polymerase (PARP) inhibitor.
  • Phase 3 trials ARIEL3 and ARI...